Announced on its homepage: “Read More » Belfast-based AMPLY raises £900k to tackle drug-resistant pathogens with AI September 26, 2022 Read More » Read more and conn…”.
Observed on the company’s website; business claims are not independently verified.
Our earliest capture with readable facts. This is our first observation, not when the company introduced these things. These website claims are not independently verified.
How it described itself
Using evolutionary biology and AI to develop next generation pharmaceuticals
AMPLY Discovery is human health animal health AI machine learning small proteins peptides novelty antivirals antifungals anticancer bioprinting beating MDR Using evolutionary biology and AI to develop
All facts above belong to this capture. Unlisted fields mean we have no readable observation, not that they were absent.
How it describes itself
Similar headlines are grouped together. The quote shown is from the last capture in each group, not necessarily the exact wording throughout that period.
Seen November 2026 · 1 capture · latest observed messagingMost of the genome is uncharted. We drew a map.
AMPLY Discovery is a UK biotech turning the regulatory genome — the part drug developers have largely ignored — into first-in-class RNA medicines for triple-negative breast cancer and high-grade serou
Life finds a way AMPLYfolio AI unlocks the digital biome to accelerate the identification of novel, next-generation therapeutics AI-derived novel biologics AMPLY Discovery uses a bespoke AI technology
May 2022 – August 2022 · 2 capturesUsing evolutionary biology and AI to develop next generation pharmaceuticals
AMPLY Discovery is human health animal health AI machine learning small proteins peptides novelty antivirals antifungals anticancer bioprinting beating MDR Using evolutionary biology and AI to develop